What You Should Know When Considering ICER’s Value Assessment Framework
Over the past several months, our Modeling & Evidence team has been busy tracking the Institute for Clinical and Economic Review’s (ICER) movements. In early February 2017, ICER released a revised Value Assessment Framework, the conceptual framework for guiding their evaluations of clinical and cost-effectiveness. After a three month open-comment[…]
A Need for Alignment: How ICER's New Cost-Effectiveness Framework Compares with the Second Panel's Recommendations
Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in[…]
How Does ICER’s Incremental Cost-Effectiveness Analysis Stack Up to Industry Practice?
In early February, the Institute for Clinical and Economic Review (ICER) presented proposed updates to its Value Assessment Framework, based largely on stakeholder feedback received during a public comment period in late 2016. These updates focused on four domains of the framework: (1) comparative clinical effectiveness; (2) incremental[…]
ICER's New Cost-Effectiveness Threshold Raises 5 Major Questions
Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should[…]